Better end points needed in primary sclerosing cholangitis trials

Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):143-144. doi: 10.1038/s41575-019-0110-5.

Authors

Alessio Gerussi¹, Pietro Invernizzi²

Affiliations

¹ Division of Gastroenterology and Center for Autoimmune Liver Diseases, San Gerardo Hospital, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
² Division of Gastroenterology and Center for Autoimmune Liver Diseases, San Gerardo Hospital, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. [email protected].

PMID: 30655632
DOI: 10.1038/s41575-019-0110-5

No abstract available

Publication types

Comment

MeSH terms

Cholangitis, Sclerosing*
Double-Blind Method
Fibroblast Growth Factors
Humans

Substances

FGF19 protein, human
Fibroblast Growth Factors